Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Bloomage Biotechnology Corp., Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Chinese Company Bloomage Biotech Forges Partnership with Japanese Firms on Regenerative Medicine
Details : RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 24, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Bloomage Biotechnology Corp., Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UDI-001
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 05, 2021
Lead Product(s) : UDI-001
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADR-002K
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Osaka University
Deal Size : Inapplicable
Deal Type : Inapplicable
ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 05, 2021
Lead Product(s) : ADR-002K
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Osaka University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 21, 2020
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADR-001
Therapeutic Area : Nephrology
Study Phase : Phase I
Recipient : Nagoya University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Clinical Trial of ADR-001 for IgA Nephropathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : ADR-001
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Recipient : Nagoya University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ADR-001 in Patients With Liver Cirrhosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 18, 2017
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable